Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- Welfare Offices to Dispatch “Advisors” to Visit Welfare Recipients and Encourage Generic Drug Use
February 27, 2012
- Health Insurance Law Revision Study Group Formed, Calling for Legal Presence for Regulatory Guidance
February 24, 2012
- Measures to Eliminate Drug Lag “Fully Implemented”: GRU Report
February 24, 2012
- Novartis Pharma’s Pasireotide Designated as Orphan Drug for Cushing’s Disease
February 24, 2012
- PAFSC Committee on New Drugs Approves Orphan Drug Designation for 3 Products
February 24, 2012
- DPJ’s PAL Subcommittee to Form Opinion on Amendment of PAL in March
February 23, 2012
- MEXT to Make Drug Education Compulsory at Junior High Schools from FY2012
February 23, 2012
- MHLW to Promote Multinational Clinical Trials in East Asia to Reduce Drug Lag
February 23, 2012
- MHLW Plans to Set Up Medical Information Database at 6 Base Locations in FY2012
February 22, 2012
- MHLW to Improve Review System Based on Regulatory Science: PFSB Director General Yoshiyuki Kikura
February 22, 2012
- MHLW Warns Manufacturers to Take Steps to Ensure Proper Use of Anti-Influenza Drugs
February 22, 2012
- MHLW Issues Notification to Publicize FPMAJ’s Crude and Kampo Drug Standards
February 20, 2012
- MHLW Issues Improvement Order to Janssen Pharmaceutical for GMP Violation
February 20, 2012
- Domestic Pharmaceutical Production Down 0.6% in 2010; First Decline in Six Years
February 20, 2012
- 105 Nu-lotan Generics from 35 Companies Approved for June Listing, 60% Pricing to Apply
February 16, 2012
- Medical Innovation Council Executive Meeting to Set Next 5-Year Plan by May
February 16, 2012
- MHLW to Revise Notification on GMP Inspection Requirements to Prepare for Participation in PIC/S
February 16, 2012
- PAFSC’s 2nd Committee on New Drugs to Discuss Approval for Pfizer Japan’s ALK Inhibitor Xalkori
February 16, 2012
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…